Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,252,817 entitled "Viruses for the Treatment of Cellular Proliferative Disorders."
The claims cover the use of modified herpes simplex viruses (HSV) to treat cellular proliferative disorders which include neoplasias (cancers). "This patent expands our intellectual property portfolio in viruses other than reovirus," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment